The North America Point of Care (POC) Molecular Diagnostics Market is exhibiting significant growth, driven by advancements in molecular diagnostic technology and rising demand for rapid and accurate testing solutions. The market size was valued at USD 2,945 Million in 2025, and is expected to reach USD 10,675 Million by 2035, expanding at a CAGR of 12.4% from 2024 to 2035. Increasing incidence of infectious diseases, growing geriatric population, and heightened awareness regarding early diagnosis of diseases are the primary factors contributing to this market surge.
The economic impact of tariffs on "North America Point of Care Molecular Diagnostics Market".
Market Growth Drivers
Technological Advancements and Product Launches: Continuous innovation in molecular testing platforms and heightened investment in R&D have made point-of-care molecular diagnostics more accessible and user-friendly. For instance, Abbott’s ID NOW platform allows for rapid and accurate molecular testing at the point of care, aiding in early disease detection and improving patient outcomes. Companies like Roche Diagnostics have also invested heavily in molecular diagnostics, developing portable solutions catering to both COVID-19 and non-COVID conditions. Such advancements have reduced turnaround times, improved sensitivity and specificity, and enabled real-time decision-making for healthcare providers.
Increased Prevalence of Infectious Diseases and Chronic Conditions: Rising prevalence of infectious diseases such as influenza, COVID-19, as well as chronic diseases requiring regular monitoring, has fueled demand for POC molecular diagnostics. For example, Cepheid’s GeneXpert system is widely deployed in North American hospitals due to its ability to rapidly detect multiple pathogens. This trend is further reinforced by government initiatives promoting early diagnosis and decentralized healthcare, which expand reach and accessibility of molecular diagnostic tools.
Market Trends
Shift towards Decentralized and Home-based Testing: The COVID-19 pandemic has accelerated the shift to decentralize diagnostic testing from centralized labs to home or point-of-care settings. Companies such as Lucira Health and Cue Health have launched molecular home-testing kits, enabling users to obtain results quickly without visiting hospitals. This trend is set to continue, driven by consumer demand for convenience, privacy, and timely results as well as payer and provider preference for cost-effective care delivery.
Integration of Connectivity and Digital Health Solutions: Manufacturers are increasingly embedding connectivity features in POC molecular diagnostic devices to facilitate data sharing, real-time result transmission, and integration with electronic medical records (EMR). For instance, BD (Becton, Dickinson and Company) has enhanced its Veritor Plus System to support cloud-based reporting, enabling clinicians to remotely track diagnostic data and better manage patient care. The ongoing adoption of digital health platforms is enabling seamless workflow integration and improved population health management.
Market Opportunity
Expansion into Non-traditional Care Settings: The demand for POC molecular diagnostics is expanding beyond hospitals and clinics to urgent care centers, pharmacies, and even workplaces. Companies like Abbott and Thermo Fisher Scientific are actively partnering with retail pharmacies to increase the availability of POC molecular tests, representing a lucrative growth opportunity as healthcare models shift toward patient-centric, decentralized care.
Development of Multiplexed Testing Panels: There is a significant opportunity for manufacturers to develop multiplexed POC molecular diagnostics capable of simultaneously detecting multiple pathogens or genetic markers. This not only improves diagnostic accuracy but also improves workflow efficiency in resource-limited and high-throughput environments.
North America Point of Care Molecular Diagnostics Market Revenue (USD Million), 2020-2035
The North America Point of Care Molecular Diagnostics Market has demonstrated a steady upward trajectory from 2020 through 2035. In 2020, market revenue stood at approximately USD 1,250 million. Growth has accelerated since 2022, driven by increased adoption of rapid tests post-COVID-19 and ongoing product innovation. By 2025, market size is expected to reach USD 2,945 million as new consumer segments are served. Sustained double-digit CAGR is forecasted, with revenues projected to surpass USD 10,675 million by 2035, reflecting expanding use cases, improved technology, and greater healthcare decentralization. Key growth milestones include widescale adoption of home-based testing and multiplexed panels in the latter half of the forecast period.
Market Share by Region, 2025
In 2025, the United States is expected to dominate the North America Point of Care Molecular Diagnostics Market, accounting for 83% of the total market share. Canada follows with a 12% share, while Mexico represents 3%. The remaining 2% is divided among other countries including Bermuda and Greenland. The market share distribution illustrates the overwhelming prevalence of robust healthcare infrastructure, advanced research, and swift adoption of diagnostic technologies in the U.S., while Canada’s share is buoyed by progressive public health initiatives. Emerging markets within North America show potential for future growth but currently represent a small fraction of overall revenues.
Recent Developments
In February 2024, Abbott announced the launch of a new molecular POCT system, ID NOW 2.0, with improved speed and enhanced menu for influenza and strep diagnostics, leveraging AI-driven interpretation. The system is currently being rolled out in urgent care centers across the U.S., demonstrating the company’s commitment to supporting decentralized and rapid disease diagnosis.
In April 2024, Cue Health received FDA Emergency Use Authorization for its at-home molecular COVID-19 and influenza test. The single-use, connected test delivers results within 25 minutes and integrates with digital health platforms. This development strengthens Cue Health’s position in the expanding home diagnostics segment, meeting growing demand for multiplex point-of-care testing.
In May 2024, Roche Diagnostics expanded its cobas® Liat system panel by adding a combined respiratory syncytial virus (RSV) and influenza A/B POCT assay. The approval was quickly followed by pilot programs in Canadian pediatric hospitals, accelerating time to result and improving outbreak management. The initiative reflects Roche’s focus on continuously broadening its POCT offerings.
Press Releases